MedinCell S.A.

Paris Stock Exchange MEDCL.PA

MedinCell S.A. Capital Expenditure for the year ending March 31, 2024: USD -1.29 M

MedinCell S.A. Capital Expenditure is USD -1.29 M for the year ending March 31, 2024, a -15.40% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

MedinCell S.A. Capital Expenditure for the year ending March 31, 2023 was USD -1.11 M, a 49.03% change year over year.
MedinCell S.A. Capital Expenditure for the year ending March 31, 2022 was USD -2.18 M, a -127.39% change year over year.
MedinCell S.A. Capital Expenditure for the year ending March 31, 2021 was USD -960.68 K, a 5.43% change year over year.
MedinCell S.A. Capital Expenditure for the year ending March 31, 2020 was USD -1.02 M, a -20.10% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Paris Stock Exchange: MEDCL.PA

MedinCell S.A.

CEO	Mr. Christophe Douat
IPO Date	Oct. 8, 2018
Location	France
Headquarters	3 rue des Frères Lumière
Employees	134
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals Vaccines

Description

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.

Key trends

Past 5 years